Revolution Medicines, Inc. (NASDAQ:RVMD) on Sunday announced new clinical data for zoldonrasib (RMC-9805), a RAS(ON) ...

Explore the evolving landscape of non-small cell lung cancer (NSCLC) treatment, where targeted therapies address ten actionable genomic alterations (AGAs). Discover innovations in EGFR mutations, ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

Zongertinib, a HER2-targeted therapy made by Boehringer Ingelheim, demonstrated promising results in HER2-mutant lung cancer.

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

The global non-small cell lung cancer market is on track for exceptional growth, driven by increasing demand for innovative treatment solutions. According to recent market projections, the market ...

Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase ...

Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this ...

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...

Diliman has identified potential biomarkers or signs that can help with early lung cancer detection with the support of the ...